MIJ821
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $276,452 | 8 | 0 |
| 2018 | $832,202 | 1 | 0 |
| 2017 | $120,528 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST IN HUMAN RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED SINGLE ASCENDING INTRAVENOUS DOSES AND A REPEATED SINGLE INTRAVENOUS DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MIJ821 IN HEALTHY VOLUNTEERS | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| A MULTI CENTER RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED ACTIVE COMPARATOR PARALLEL GROUP PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF MIJ821 IN PATIENT WITH TREATMENT RESISTANT DEPRESSIO | Novartis Pharmaceuticals Corporation | $13,344 | 0 |
Top Doctors Receiving Payments for MIJ821
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $1.2M | 10 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 0
- Transactions 10
About MIJ821
MIJ821 is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $276,452 was paid across 8 transactions to 0 doctors.
The most common payment nature for MIJ821 is "Unspecified" ($1.2M, 100.0% of total).
MIJ821 is associated with 2 research studies, including "A FIRST IN HUMAN RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED SINGLE ASCENDING INTRAVENOUS DOSES AND A REPEATED SINGLE INTRAVENOUS DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MIJ821 IN HEALTHY VOLUNTEERS" ($1.2M).